arrow
G

Gerburg M. Wulf

beth israel dea-coness medical center
H指数:52
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A noncanonical function of the tyrosine degradation enzyme FAH drives CDK4/6 inhibitor resistance in breast cancer

酪氨酸降解酶FAH的非典型功能驱动乳腺癌中CDK4/6抑制剂的耐药性

2026-09-300
OAAI
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer

NF1基因改变与CDK4/6抑制剂耐药在激素受体阳性转移性乳腺癌中的从临床到基础研究的转化分析

2025-06-270
PRE
Targeting transcription factors through an IMiD independent zinc finger domain

通过IMiD非依赖性锌指域靶向转录因子

2025-05-140
OA
Effect of testosterone therapy on breast tissue composition and mammographic breast density in trans masculine individuals
2024-07-021
OAAI
A bedside-to-bench translational analysis demonstrates that NF1 alterations promote CDK4/6 inhibitor (CDK4/6i) resistance in hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
2024-05-020
PRE
Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations
2024-05-020
PRE
A phase I trial of the PI3K inhibitor (PI3Ki) copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer
2024-05-020
PRE
Reciprocal antagonism of PIN1-APC/CCDH1 governs mitotic protein stability and cell cycle entry

PIN1-APC/CCDH1的相互拮抗作用控制有丝分裂蛋白稳定性和细胞周期进入

2024-04-154
OAAI
NCI10217: Phase Ib biomarker-driven tumor-agnostic combination (Combo) trial of copanlisib (Copa) and olaparib (Ola) in molecularly-selected patients (pts) with advanced cancers with PIK3CA hotspot, PTEN and DNA damage response (DDR) mutations
2024-04-050
PRE
Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations

变构PI3Kα 抑制克服了继发性PIK3CA突变介导的对正构抑制剂的靶向抗性

2023-10-3114
OAAI
Olaparib plus /- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial
2023-04-145
PRE